CMP-2901
Pfizer India , a 100% free company is a subsidary of Pfizer Inc., the world’s premiere biopharmaceutical corporationan American multinational pharmaceutical corporation headquartered in New York City with a history of more than 170 Years. Pfizer Limited has a portfolio of over 150 products across 15 therapeutic areas. Its top brands include Prevenar 13, Lyrica, Eliquis, Enbrel, Becosules, Gelusil and Corex range of products. The company enjoys a unique advantage of access to Pfizer Inc’s global portfolio of therapies for introduction in the Indian market.
Pfizer came to the Indian market in the year 1950 through a company named Dumex Limited. The first production facility was set up at Darukhanna in Mumbai, where products like Protinex and Isonex (isoniazid – an anti -TB drug) were manufactured.
Parent History-:
Pfizer was founded in 1849 by German-American. Over the years Pfizer has intotal merged or acquired more than 50 companies all over the world. It is one of the world’s largest pharmaceutical companies. It is listed on the New York Stock Exchange, and its shares have been a component of the Dow Jones Industrial Average since 2004. Pfizer ranked No. 57 on the 2018 Fortune 500 list of the largest United States corporations by total revenue. In 2018, Pfizer announced a joint merger of their consumer healthcare division with UK pharma giant GlaxoSmithKline; the British company will maintain a controlling share (listed at 68%).
Financials-: Company has cash and equivalents of about 1900 cr as of march 2019 which puts it as a great advantage to spend on better R&D as compared to other companies struggling to manage working capital. Apart from the company does not have any debt where as company has reserves of around 3000Cr. Promoters hold more tha 63% shares of the company.Sales growth over the past several years have remained stagnat while net profit has been increasing consistently. Going forward with the introduction of new drugs and better market conditions , we do expect capital preservation to long term value creation happening in the stock.
